Testing semaglutide for weight loss in people with advanced lung disease
Tests whether semaglutide is tolerable in adults with advanced lung disease and obesity.
Plain-language title generated from the registry record
Registry title: Feasibility of Semaglutide in Advanced Lung Disease
Key facts
- Where
- Philadelphia, United StatesSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT05746039, who can take part
Where in United States
- University of Pennsylvania Perelman School of MedicinePhiladelphia, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Pennsylvania
- Trial code
- NCT05746039
- Record updated
- 21 April 2026
- Original description
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease.Read full original descriptionShow less
Feasibility of Semaglutide Therapy for Weight Loss in Advanced Lung Disease: A Pilot Study
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease.
The main question[s] it aims to answer are:
1. Are patients with advanced lung disease able to tolerate semaglutide therapy? 2. Are we able to titrate semaglutide therapy to a target weight?
Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw before and after 12-weeks of semaglutide therapy. While on therapy, subjects will be surveyed regarding any adverse events or side effects.
Inclusion: Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension; Age > 18; BMI > 30 kg/m2; Requires supplemental oxygen on exertion; Stable treatment regimen X 90 days; Use of disease-modifying therapy.
Exclusion: Use of weight loss medication in last 90 days; Prior suicide attempt; Diabetes; History of gastroparesis; History of scleroderma; Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2); Uncontrolled thyroid disease; History of acute/chronic pancreatitis; Pregnant or Breastfeeding; Recent weight loss; Recent or chronic GI complaints; Hospitalized at time of evaluation; Suicidal ideation in last 90 days; Presence of a pacemaker or defibrillator.